Angela Dispenzieri, MD, of the Mayo Clinic, Rochester, MN, discusses potential novel frontline treatments for amyloidosis, highlighting key data from pivotal clinical trials. Dr Dispenzieri discusses the results from the most awaited Phase III ANDROMEDA trial (NCT03201965) investigating daratumumab plus cyclophosphamide, bortezomib and dexamethasone (CyBorD) compared to CyBorD alone in newly diagnosed patients with amyloid light-chain amyloidosis. The study yielded a complete remission rate of 53% with the addition of daratumumab to CyBorD as opposed to 18%. Dr Dispenzieri also comments on the Phase III EMN-03 trial (NCT01277016) comparing the efficacy and safety of bortezomib, melphalan, and dexamethasone with melphalan and dexamethasone. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.

свернуть